Company news

Novavax, Inc. news in 2025

Novavax, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Novavax to Participate in Jefferies London Healthcare Conference

November 11, 2025

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

November 5, 2025

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

November 3, 2025

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

October 29, 2025

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

October 21, 2025

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

October 6, 2025

Novavax Announces Progress on Sanofi Agreement

September 29, 2025

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

September 3, 2025

Novavax to Participate in the Cantor Global Healthcare Conference

September 2, 2025

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

August 26, 2025

Novavax Announces Convertible Debt Refinancing

August 20, 2025

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

August 5, 2025

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

July 29, 2025

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

July 23, 2025

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

June 10, 2025

Novavax to Participate in Upcoming Investor Conferences

May 28, 2025

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 18, 2025

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

May 7, 2025

Novavax to Participate in BofA Securities 2025 Health Care Conference

May 6, 2025

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

May 4, 2025

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

April 30, 2025

Novavax Appoints Charles Newton to Board of Directors

April 28, 2025

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

April 14, 2025

Novavax Announces Changes to Board of Directors

March 10, 2025

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

February 26, 2025

Novavax to Participate in Upcoming March Investor Conferences

February 26, 2025

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

February 19, 2025

Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

January 22, 2025

Calls in 2025

Decks in 2025